Literature DB >> 24461491

Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.

Zaw W Myint1, Jeremy M Sen2, Nicole L Watts2, Thomas J Druzgal3, Barnett R Nathan4, Melanie D Ward4, James E Boyer5, Paula M Fracasso5.   

Abstract

Entities:  

Keywords:  Metastatic colorectal cancer; Posterior reversible encephalopathy; RPLS; Regorafenib; VEGF multikinase inhibitor; syndrome

Mesh：

Substances：

Year:  2013        PMID： 24461491     DOI： 10.1016/j.clcc.2013.12.003

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN： 1533-0028            Impact factor:   4.481


× No keyword cloud information.
  10 in total

1.  Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors:  Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal:  Invest New Drugs       Date:  2014-05-23       Impact factor: 3.850

Review 2.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

3.  Imaging Patterns and Outcome of Posterior Reversible Encephalopathy Syndrome During Childhood Cancer Treatment.

Authors:  Raja B Khan; Zsila S Sadighi; Jennifer Zabrowski; Amar Gajjar; Sima Jeha
Journal:  Pediatr Blood Cancer       Date:  2015-10-15       Impact factor: 3.167

4.  Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer.

Authors:  Soundouss Raissouni; Zarqa Quraishi; Mohammed Al-Ghamdi; Jose Monzon; Patricia Tang; Michael M Vickers
Journal:  BMC Res Notes       Date:  2015-10-05

5.  Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.

Authors:  Michela Quirino; Sabrina Rossi; Giovanni Schinzari; Michele Basso; Antonia Strippoli; Alessandra Cassano; Carlo Barone
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

6.  Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.

Authors:  Yoko Osawa; Rikako Gozawa; Keisuke Koyama; Takeo Nakayama; Tadashi Sagoh; Hiroshi Sunaga
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

7.  Daptomycin-Induced Posterior Reversible Encephalopathy Syndrome (PRES).

Authors:  A Bitar De Zayas-Enriquez; C Soper
Journal:  Case Rep Neurol Med       Date:  2019-02-24

8.  Reversible posterior leukoencephalopathy syndrome following apatinib for gastric cancer in an adult: A case report and a review of the literature.

Authors:  Yajuan Lv; Yan Zhang; Jiandong Zhang; Ning Liang; Fengjun Liu; Ruixue Liu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

9.  Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects.

Authors:  Sarah Hamidi; Andrée Boucher; Bernard Lemieux; Geneviève Rondeau; Rebecca Lebœuf; Louis-Georges Ste-Marie; Xuan Kim Le; Hortensia Mircescu
Journal:  J Endocr Soc       Date:  2022-03-23

Review 10.  Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.

Authors:  Young Kwang Chae; Lauren Chiec; Scott K Adney; Josh Waitzman; Ricardo Costa; Benedito Carneiro; Maria Matsangou; Mark Agulnik; Peter Kopp; Frank Giles
Journal:  Oncotarget       Date:  2018-06-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.